Klotho Neurosciences Inc. is a pharmaceutical company. It specializes in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system which are seen as key developments in treating neurodegenerative and age-related disorders. Klotho Neurosciences Inc., formerly known as ANEW MEDICAL INC., is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-6.15M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 8.39 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -1779.01% |
| Return on Assets (Trailing 12 Months) | -275.01% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.29 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.29 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.02 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.36 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 32.49M |
| Free Float | 23.82M |
| Market Capitalization | $6.22M |
| Average Volume (Last 20 Days) | 34.11M |
| Beta (Past 60 Months) | -1.10 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 26.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 20.07% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |